FGP
NVO

Foyston, Gordon, & Payne’s Novo Nordisk NVO Stock Holding History

Foyston, Gordon, & Payne’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-16,736
Closed -$937K – 65
2021
Q4 		$937K Hold
16,736
– – 0.22% 53
2021
Q3 		$803K Hold
16,736
– – 0.2% 52
2021
Q2 		$701K Sell
16,736
-28,896
-63% -$1.12M 0.17% 61
2021
Q1 		$1.54M Sell
45,632
-12
-0% -$427 0.36% 53
2020
Q4 		$1.59M Sell
45,644
-52
-0.1% -$1.8K 0.38% 52
2020
Q3 		$1.59M Sell
45,696
-120
-0.3% -$4K 0.41% 52
2020
Q2 		$1.5M Sell
45,816
-158
-0.3% -$5.04K 0.37% 51
2020
Q1 		$1.38M Buy
45,974
+110
+0.2% +$3.27K 0.36% 48
2019
Q4 		$1.33M Sell
45,864
-71,890
-61% -$1.99M 0.25% 49
2019
Q3 		$3.04M Sell
117,754
-3,038
-3% -$76.8K 0.61% 36
2019
Q2 		$3.08M Sell
120,792
-1,974
-2% -$48.8K 0.58% 34
2019
Q1 		$3.21M Sell
122,766
-414
-0.3% -$10.2K 0.61% 31
2018
Q4 		$2.84M Sell
123,180
-1,176
-0.9% -$26.1K 0.57% 35
2018
Q3 		$2.93M Buy
124,356
+1,268
+1% +$30.9K 0.5% 37
2018
Q2 		$2.84M Sell
123,088
-90,008
-42% -$2.14M 0.52% 41
2018
Q1 		$5.25M Sell
213,096
-5,888
-3% -$155K 1.01% 28
2017
Q4 		$5.88M Sell
218,984
-123,960
-36% -$3.15M 1.12% 28
2017
Q3 		$8.26M Buy
342,944
+113,882
+50% +$2.57M 1.43% 23
2017
Q2 		$4.91M Sell
229,062
-5,722
-2% -$115K 1.06% 29
2017
Q1 		$4.02M Buy
234,784
+46,670
+25% +$813K 0.87% 34
2016
Q4 		$3.37M Buy
+188,114
New +$3.41M 0.8% 42

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Foyston, Gordon, & Payne's NVO Position: Q1 2022 in Review

Foyston, Gordon, & Payne sold out of Novo Nordisk (NVO) in Q1 2022, closing a stake of 16,736 shares — an estimated $937K sold.

Foyston, Gordon, & Payne first reported a position in NVO in Q4 2016 and held it in 21 quarters. The position peaked at $8.26M in Q3 2017. 902 funds tracked by Wall St. Rank hold NVO as of Q1 2022.

  • Foyston, Gordon, & Payne reported no remaining Novo Nordisk position as of Q1 2022 after selling out during the quarter.
  • Foyston, Gordon, & Payne sold 16,736 Novo Nordisk shares in Q1 2022, an estimated $937K.
  • Foyston, Gordon, & Payne first reported a position in Novo Nordisk in Q4 2016 and held it in 21 quarters.
  • Foyston, Gordon, & Payne's Novo Nordisk position peaked at $8.26M in Q3 2017.
  • 902 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2022.

Based on Foyston, Gordon, & Payne's 13F filing for Q1 2022, filed 27 Apr 2022.